Stopping Ozempic or Mounjaro? Study Projects Rapid Weight Regain
New research reveals how quickly patients regain weight after stopping popular GLP-1 medications like Wegovy and Zepbound.
Read AnalysisHow Semaglutide Cuts Calories Even When Hunger Returns
A new 60-week study reveals that semaglutide helps people eat less long-term, even after its subjective appetite-suppressing effects begin to fade.
Read AnalysisOral Semaglutide Slashes Liver Fat and Body Weight
A new clinical trial shows oral semaglutide significantly reduces body fat and improves liver health in people without diabetes.
Read AnalysisPopular GLP-1 Medications Linked to Higher Hair Loss Risk
A new study reveals a significant link between popular GLP-1 receptor agonists and an increased risk of temporary hair shedding.
Read AnalysisOral Semaglutide Shows Promise in Reducing Heavy Drinking
A new clinical trial suggests the blockbuster drug semaglutide could help people struggling with alcohol use disorder cut back on heavy drinking.
Read AnalysisDIY Semaglutide: The Dangerous Risks of Grey Market Peptides
A new study reveals that untrained adults attempting to prepare and inject unprescribed, grey-market semaglutide make critical errors over half the time.
Read AnalysisNovel Dual-Action Weekly Injection Successfully Redefines Obesity Treatment
A new phase 3 clinical trial reveals that survodutide, a weekly dual-agonist injection, helps adults achieve significant weight reduction.
Read AnalysisDual-Drug Therapy Outperforms Semaglutide Alone for Weight Loss
A combination of cagrilintide and semaglutide helped patients lose significantly more weight than semaglutide alone in a new clinical trial.
Read AnalysisTirzepatide Beats Semaglutide for Faster, Greater Weight Loss
A massive new real-world study reveals that tirzepatide delivers faster and more significant weight loss with fewer side effects than semaglutide.
Read Analysis